U.S. Pharmaceuticals & Biotech Most Popular Stocks

AnaptysBio

Market Cap: US$619.9m

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics.

Bicara Therapeutics

Market Cap: US$610.6m

A clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.

Compass Therapeutics

Market Cap: US$598.8m

A clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States.

Olema Pharmaceuticals

Market Cap: US$573.1m

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

Oruka Therapeutics

Market Cap: US$571.9m

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Arvinas

Market Cap: US$567.5m

A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Arcturus Therapeutics Holdings

Market Cap: US$555.3m

Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.

Rigel Pharmaceuticals

Market Cap: US$543.1m

A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.

Erasca

Market Cap: US$541.8m

A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Personalis

Market Cap: US$537.4m

Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.

Eton Pharmaceuticals

Market Cap: US$534.5m

A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

COMPASS Pathways

Market Cap: US$531.5m

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

Verastem

Market Cap: US$529.9m

A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

Bicycle Therapeutics

Market Cap: US$525.3m

A clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.

Ocugen

Market Cap: US$512.2m

A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.

Zevra Therapeutics

Market Cap: US$502.4m

A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

Prothena

Market Cap: US$501.7m

A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.

Standard BioTools

Market Cap: US$500.4m

Develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

Esperion Therapeutics

Market Cap: US$489.9m

A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.

Solid Biosciences

Market Cap: US$485.9m

Develops therapies for neuromuscular and cardiac diseases in the United States.

Lexicon Pharmaceuticals

Market Cap: US$483.3m

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.

Corvus Pharmaceuticals

Market Cap: US$482.9m

A clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.

REGENXBIO

Market Cap: US$481.9m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

Cryoport

Market Cap: US$478.6m

Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.

Monopar Therapeutics

Market Cap: US$450.7m

A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Fulcrum Therapeutics

Market Cap: US$446.3m

A clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

XOMA Royalty

Market Cap: US$444.6m

Operates as a biotech royalty aggregator in the United States and the Asia Pacific.

Emergent BioSolutions

Market Cap: US$442.3m

A life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.

Larimar Therapeutics

Market Cap: US$436.5m

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Cytek Biosciences

Market Cap: US$433.8m

A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.

Alumis

Market Cap: US$430.8m

A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

Inhibrx Biosciences

Market Cap: US$430.2m

A clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

ALT5 Sigma

Market Cap: US$427.3m

Provides blockchain-powered technologies worldwide.

Autolus Therapeutics

Market Cap: US$415.2m

A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.

Astria Therapeutics

Market Cap: US$410.3m

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.

I-Mab

Market Cap: US$409.8m

A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.